Section Arrow
Quote
TELO.NASDAQ
- Telomir Pharmaceuticals
Quotes are at least 15-min delayed:2025/06/10 00:30 EDT
Last
 1.98
-0.17 (-7.91%)
Day High 
2.49 
Prev. Close
2.15 
1-M High
2.7788 
Volume 
444.66K 
Bid
1.97
Ask
2.1
Day Low
1.95 
Open
2.12 
1-M Low
1.87 
Market Cap 
63.99M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.07 
20-SMA 2.26 
50-SMA 2.55 
52-W High 8.4 
52-W Low 1.87 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.40/-0.28
Enterprise Value
63.99M
Balance Sheet
Book Value Per Share
-0.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0762+0.0263+52.71%-- 
CTXRCitius Pharmaceuticals Inc1.37+0.519+60.99%-- 
RXRXRecursion Pharmaceuticals5.37-0.12-2.19%-- 
SNPXSynaptogenix3.48+1.07+44.40%2.76PE
CARMCarisma Therapeutics0.2268+0.0329+16.97%-- 
Quotes are at least 15-min delayed：2025/06/10 00:30 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.